These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24508819)

  • 1. Fragile X syndrome neurobiology translates into rational therapy.
    Braat S; Kooy RF
    Drug Discov Today; 2014 Apr; 19(4):510-9. PubMed ID: 24508819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential therapeutic interventions for fragile X syndrome.
    Levenga J; de Vrij FM; Oostra BA; Willemsen R
    Trends Mol Med; 2010 Nov; 16(11):516-27. PubMed ID: 20864408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
    Berry-Kravis E
    Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-based approaches to treating fragile X.
    Dölen G; Carpenter RL; Ocain TD; Bear MF
    Pharmacol Ther; 2010 Jul; 127(1):78-93. PubMed ID: 20303363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.
    Hampson DR; Adusei DC; Pacey LK
    Biochem Pharmacol; 2011 May; 81(9):1078-86. PubMed ID: 21333634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in understanding fragile X syndrome and related disorders.
    Rooms L; Kooy RF
    Curr Opin Pediatr; 2011 Dec; 23(6):601-6. PubMed ID: 22001764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From intellectual disability to new treatment modalities of fragile X syndrome].
    Jønch AE; Timshel S; Carlsen Lunding JM; Grønskov K; Brøndum-Nielsen K
    Ugeskr Laeger; 2014 Feb; 176(9A):V06130350. PubMed ID: 25350408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating molecular advances in fragile X syndrome into therapy: a review.
    Hagerman RJ; Des-Portes V; Gasparini F; Jacquemont S; Gomez-Mancilla B
    J Clin Psychiatry; 2014 Apr; 75(4):e294-307. PubMed ID: 24813413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model.
    Busquets-Garcia A; Maldonado R; Ozaita A
    Int J Biochem Cell Biol; 2014 Aug; 53():121-6. PubMed ID: 24831882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials.
    Braat S; Kooy RF
    Neuropharmacology; 2015 Jan; 88():48-54. PubMed ID: 25016041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders.
    Braat S; Kooy RF
    Neuron; 2015 Jun; 86(5):1119-30. PubMed ID: 26050032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Courting a cure for fragile X.
    Dölen G; Bear MF
    Neuron; 2005 Mar; 45(5):642-4. PubMed ID: 15748838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome.
    Valenti D; de Bari L; De Filippis B; Henrion-Caude A; Vacca RA
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():202-17. PubMed ID: 24548784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomedical research. A fix for fragile X syndrome?
    Miller G
    Science; 2006 Apr; 312(5773):521. PubMed ID: 16645065
    [No Abstract]   [Full Text] [Related]  

  • 15. Fragile X syndrome: an update on developing treatment modalities.
    Healy A; Rush R; Ocain T
    ACS Chem Neurosci; 2011 Aug; 2(8):402-10. PubMed ID: 22860169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.
    Berry-Kravis EM; Lindemann L; Jønch AE; Apostol G; Bear MF; Carpenter RL; Crawley JN; Curie A; Des Portes V; Hossain F; Gasparini F; Gomez-Mancilla B; Hessl D; Loth E; Scharf SH; Wang PP; Von Raison F; Hagerman R; Spooren W; Jacquemont S
    Nat Rev Drug Discov; 2018 Apr; 17(4):280-299. PubMed ID: 29217836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragile X syndrome: from molecular genetics to therapy.
    D'Hulst C; Kooy RF
    J Med Genet; 2009 Sep; 46(9):577-84. PubMed ID: 19724010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathways to drug development for autism spectrum disorders.
    Hampson DR; Gholizadeh S; Pacey LK
    Clin Pharmacol Ther; 2012 Feb; 91(2):189-200. PubMed ID: 22205199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing glutamate signaling pays off in fragile X.
    Bassell GJ; Gross C
    Nat Med; 2008 Mar; 14(3):249-50. PubMed ID: 18323845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.